anti-CD19-CAR vector-transduced T cells
PreclinicalCell therapy
Novo Nordiskanti-CD19-CAR vector-transduced T cells is one of 8 biologic programs targeting B-cell Malignancy. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in B-Cell Malignancy
#DrugCompanyPhaseTrials
1LUNSUMIO
RochePreclinical
COLUMVI
RochePreclinical
Gazyva
RochePreclinical
Beqalzi
BBeOne Medicines
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
BGB-16673
BBeOne Medicines
Preclinical
Tacabrutideg
MMassachusetts General Hospital
Preclinical
anti-CD19-CAR vector-transduced T cells
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
B-cell Malignancy1 trial
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Unknown status·—·N/A·NCT01864889·12 enrolled
Mantle Cell Lymphoma1 trial
CART-19 Immunotherapy in Mantle Cell Lymphoma
Unknown status·—·Phase 1/2·NCT02081937·2 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company